Besides generics, Dr. Reddy’s has committed a lot of resources to develop its biosimilars as well as new chemical entity business. Biosimilars have been seen as a growth engine for large, capable ...

Following the success of our previous roundtables, during which research leaders exchanged ideas on data issues and how they are overcoming them, this intimate session (limited to 6–8 participants) ...

By understanding a patient’s unique genetic profile, biomarker readings and lifestyle information, doctors could tailor the ...

The coolest data management and integration tool companies of the 2025 Big Data 100 include Informatica, Airbyte, Confluent ...

Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI.  | Bayer is ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

"Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

Is your organization simply ticking compliance boxes, or are you genuinely fostering patient trust and safety in the "era of ...

China is not as big a player in the manufacturing of key ingredients used to make brand and generic medicines as previously ...

It's been nearly 20 years since Tom Cruise 's infamous outburst on the Today show, where he passionately railed against antidepressants and called psychiatry a 'pseudoscience.' ...

I n an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the ...